Cabergoline linked to significant reduction in breast cancer risk

An international research team, including scientists from the Spanish National Research Council (CSIC), has identified a potential new pathway for preventing breast cancer following pregnancy. According to a study published in the journal Cancer Discovery, the use of cabergoline—a medication used to suppress milk production—is associated with an approximately 70% reduction in the risk of developing breast cancer.

The findings are based on a retrospective analysis of medical records from over 150,000 women in Spain and Norway, alongside laboratory experiments. In mouse models carrying BRCA1 and TP53 gene mutations, which are linked to aggressive tumors, a single dose of the drug reduced tumor occurrence by approximately half.

Researchers explain that the drug may influence the process of mammary involution, the natural biological cleaning process that occurs after lactation ends. While the observational data shows a strong correlation, researchers emphasize that clinical trials are necessary to confirm whether cabergoline can serve as a direct preventive measure and a less aggressive alternative to current preventative strategies.